Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Conditions
Interventions
Isatuximab SAR650984
Bortezomib
+2 more
Locations
104
United States
Investigational Site Number: 8400006
Fort Myers, Florida, United States
Investigational Site Number: 8400004
St. Petersburg, Florida, United States
Investigational Site Number: 8400007
Kansas City, Missouri, United States
Investigational Site Number: 8400005
Nashville, Tennessee, United States
Investigational Site Number: 8400001
Houston, Texas, United States
Investigational Site Number : 0360003
Liverpool, New South Wales, Australia
Start Date
December 7, 2017
Primary Completion Date
April 5, 2026
Completion Date
June 30, 2027
Last Updated
November 27, 2024
NCT06356571
NCT05334069
NCT05312255
NCT04508790
NCT04876248
NCT04640779
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions